XNPT Share Price

Open 7.03 Change Price %
High 7.07 1 Day 0.05 0.71
Low 7.02 1 Week 0.00 0.00
Close 7.07 1 Month 0.00 0.00
Volume 2615875 1 Year 0.00 0.00
52 Week High 68.68
52 Week Low 48.16
XNPT Important Levels
Resistance 2 7.12
Resistance 1 7.10
Pivot 7.05
Support 1 7.04
Support 2 7.02
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
ASTI 0.00 0.00%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
TEAR 3.34 89.77%
SCHS 0.05 66.67%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
TOPS 0.26 23.81%
BONT 0.80 17.65%
HAUP 0.07 16.67%
PLUG 2.44 15.09%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

XenoPort, Inc. (NASDAQ: XNPT)

XNPT Technical Analysis 5
As on 5th Jul 2016 XNPT Share Price closed @ 7.07 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 5.44 & Strong Buy for SHORT-TERM with Stoploss of 5.81 we also expect STOCK to react on Following IMPORTANT LEVELS.
XNPT Target for July
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
XNPT Other Details
Segment EQ
Market Capital 330802368.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.xenoport.com
XNPT Address
XNPT
3410 Central Expressway
Santa Clara, CA 95051
United States
Phone: 408-616-7200
XNPT Latest News
Arbor Pharmaceuticals Completes Successful Tender Offer for Shares of XenoPort   Business Wire (press release)   - 05th Jul 16
Arbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR Act ...   Business Wire (press release)   - 16th Jun 16
Why Xenoport, Inc. Stock Jumped 61.1% in May   Motley Fool   - 04th Jun 16
BioSurplus To Auction Research Equipment from the Laboratories of XenoPort, Inc.   PR Newswire (press release)   - 24th May 16
Why XenoPort, Inc. Is Skyrocketing 56.6% Today   Motley Fool   - 23rd May 16
Dr. Reddy's Laboratories and XenoPort Enter into a US Licensing Agreement for ...   Business Wire (press release)   - 28th Mar 16
XenoPort: Buyout Appears Imminent   Seeking Alpha   - 18th Feb 16
XenoPort Arguably Undervalued, But Low On Options   Seeking Alpha   - 02nd Feb 16
XenoPort (XNPT) Stock Plunged After Psoriasis Drug's Negative Side Effects   TheStreet.com   - 16th Sep 15
Xenoport: Significant Growth Potential On Horizant Sales And A Solid Pipeline   Seeking Alpha (registration)   - 03rd Feb 15
Interactive Technical Analysis Chart XenoPort, Inc. ( XNPT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on XenoPort, Inc.
XNPT Business Profile
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally for the treatment of neurological disorders. The product candidates are prodrugs that are created by modifying the chemical structure of marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug. The Company focuses its development and commercialization efforts on treatments of diseases with unmet medical needs, with an emphasis on central nervous system disorders. The products are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug. In April 2011, the United States Food and Drug Administration (FDA), approved the Company�s first product, known in the United States as Horizant (gabapentin enacarbil) Extended-Release Tablets, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults.